University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer ...

Immunotherapy has changed the way physicians treat cancer patients. This approach to therapy targets the immune system to redirect cells toward the tumor. | Immunology ...

Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new UVA Cancer Center research ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...

University of Virginia Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut ...

UVA Cancer Center researchers have explained the failure of immune checkpoint therapy for ovarian cancer by discovering how gut bacteria interfere with the treatment.

The high prevalence of sarcopenia in patients with ovarian and endometrial cancers underscores the importance of early ...

Researchers from Rice University and Baylor College of Medicine have developed a new treatment that eliminates advanced-stage ...

Tumor immune evasion mechanisms could be reversed by activating intracellular antiviral immune responses. It has been reported that the use of DNA methyltransferase (DNMT) inhibitors combined with ...

Ovarian tumors, often detected incidentally, pose a diagnostic challenge that requires careful management. Decisions depend on assessing the malignancy risk and addressing patient symptoms. For benign ...

OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today ...